Suchergebnisse

Regeneron (REGN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a

Wall Street analysts forecast that Regeneron (REGN) will report quarterly earnings of $10.00 per share in its upcoming release, pointing to a year-over-year decline of 22.4%. It is anticipated

Regency Centers (REG) came out with quarterly funds from operations (FFO) of $1.21 per share, beating the Zacks Consensus Estimate of $1.2 per share. This compares to FFO of $1.16 per share a year

Regeneron (REGN) came out with quarterly earnings of $14.29 per share, beating the Zacks Consensus Estimate of $10 per share. This compares to earnings of $12.89 per share a year ago. These figures

For the quarter ended June 2026, Regeneron (REGN) reported revenue of $4.29 billion, up 16.7% over the same period last year. EPS came in at $14.29, compared to $12.89 in the year-ago quarter.

The

Regions Financial Corporation RF is scheduled to report second-quarter 2026 results on July 17, 2026, before the opening bell. Quarterly earnings and revenues are expected to register year-over-year

Regency Centers Corp. REG is slated to report second-quarter 2026 results on July 29, after the closing bell. The company’s quarterly results are likely to display year-over-year growth in revenues

Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD and Libtayo when biotech giant Regeneron Pharmaceuticals, Inc. REGN, reports second-quarter 2026 results on July 30.

Regeneron Pharmaceuticals REGN reported second-quarter 2026 adjusted earnings per share (EPS) of $14.29, which beat the Zacks Consensus Estimate of $10.00 and increased from $12.89 recorded in the

Regency Centers Corporation REG reported second-quarter 2026 NAREIT funds from operations (FFO) per share of $1.21, beating the Zacks Consensus Estimate of $1.20 by 0.8%. The metric increased 4.3%

Meta Platforms (META) closed at $656.73 in the latest trading session, marking a -1.86% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.79% for the day

In the latest close session, Dell Technologies (DELL) was down 1.81% at $427.11. The stock's change was less than the S&P 500's daily loss of 0.79%. On the other hand, the Dow registered a loss of

In the latest close session, Axon Enterprise (AXON) was down 3.32% at $547.00. The stock's change was less than the S&P 500's daily loss of 0.79%. On the other hand, the Dow registered a loss of

Regional banks continue to operate amid changing interest rate dynamics, evolving regulatory requirements and ongoing demand for diversified financial services. Within this backdrop, Hawthorn

West Pharmaceutical Services, Inc. WST is well positioned for growth, backed by strong demand for HVPs, expanding GLP-1 drug programs and regulatory-driven Annex 1 conversions. However, tariff

Symbotic Inc. (SYM) closed at $41.98 in the latest trading session, marking a -1.55% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.51% for the day